Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Linagliptin

Linagliptin

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Linagliptin

43 trials tracked of Linagliptin: 28 in phase 3 or 4 and 2 with published results. The most-cited published study has 103 citations.

43Trials tracked
28Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 10 Phase 3 18 Phase 2 2 Phase 1 9 Other / NA 4
  1. Phase 3 Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM Completed · 103 cited
  2. Phase 4 Linagliptin's Effect on CD34+ Stem Cells Completed · 46 cited
  3. Phase 4 The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects Completed
  4. Phase 4 ADA Linagliptin in Long Term Care Completed
  5. Phase 4 Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Completed
  6. Phase 4 Effects of Linagliptin on Endothelial Function Completed
Show 37 more trials
  1. Phase 4 The Effect of Linagliptin on Mitochondrial and Endothelial Function Completed
  2. Phase 4 Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) Completed
  3. Phase 4 Linagliptin Inpatient Trial Completed
  4. Phase 4 Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes Completed
  5. Phase 4 Linagliptin as Add on to Basal Insulin in the Elderly Completed
  6. Phase 3 A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate Completed
  7. Phase 3 Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes Completed
  8. Phase 3 Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes Completed
  9. Phase 3 Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients Completed
  10. Phase 3 Comprehensive Add on Study in Japan Completed
  11. Phase 3 Linagliptin Add-on to Insulin Background Therapy Completed
  12. Phase 3 Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus Completed
  13. Phase 3 Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control Completed
  14. Phase 3 Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone Completed
  15. Phase 3 Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes Completed
  16. Phase 3 Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment Completed
  17. Phase 3 Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study Completed
  18. Phase 3 CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Completed
  19. Phase 3 Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes Completed
  20. Phase 3 BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes Completed
  21. Phase 3 Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy Completed
  22. Phase 3 Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control Completed
  23. Phase 2 Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes Completed
  24. Phase 2 The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients Completed
  25. Phase 1 Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects Completed
  26. Phase 1 Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects Completed
  27. Phase 1 Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation) Completed
  28. Phase 1 Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets Completed
  29. Phase 1 This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills Completed
  30. Phase 1 Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®. Completed
  31. Phase 1 This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood Completed
  32. Phase 1 Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects. Completed
  33. Phase 1 Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects Completed
  34. N/A Real World Glycemic Effectiveness of Linagliptin Completed
  35. N/A Comparison of Type 2 Diabetes Pharmacotherapy Regimens Completed
  36. N/A Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy Completed
  37. N/A Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management Completed

Showing the 43 most-cited and recently-updated of 43 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.